Navigation Links
Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Date:11/13/2013

luted net loss per share of $15.98 for the same period in 2012.  The comparability of net loss per share for the periods presented is significantly impacted by our initial public offering and concurrent common stock issuances in October 2012, and our public offering of common stock in July 2013.

Regulus recognized revenue of $6.1 million for the three months ended September 30, 2013, compared to $2.8 million for the same period in 2012.  Revenue during these periods consisted primarily of amortization of upfront payments received from our strategic alliances and collaborations, which is recognized over the estimated period of performance.  Revenue in the three months ended September 30, 2013 included $5.4 million from the Sanofi collaboration and license agreement and $0.5 million from the AstraZeneca collaboration and license agreement.  On a comparative basis, revenue increased in the three months ended September 30, 2013 primarily due to the incremental recognition of $3.6 million from the change in our estimated period of performance for the research term within the Sanofi collaboration and license agreement, which originally expired in June 2013, but was effectively extended through the end of December 2013 under the terms of our Option Agreement with Sanofi. 

Research and development expenses were $7.1 million for the three months ended September 30, 2013, compared to $5.2 million for the same period in 2012.  The increase was substantially attributable to IND-enabling activities for RG-101 during the quarter.  No such costs were incurred in the same period in 2012.  The Company expects our research and development expenses to increase over the coming quarters to the extent it commences clinical studies and initiates additional IND-enabling activities.

General and administrative expenses were $1.9 million for t
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
2. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
3. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
4. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
5. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
6. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
7. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
8. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
9. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
10. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
11. Regulus to Present at Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... October 22, 2014 A new ... Market (Product type, Form, End user, Application and Geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... market. Based on key trends tracked, it is anticipated ... $7.9 billion by 2020, registering a CAGR of 6.2% ...
(Date:10/22/2014)...   BioNano Genomics , the genome mapping ... to purchase an Irys™ System . Among them ... (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope (The ... comprehensive view of a genome was a major ... deliver the scalability or reliability to detect and ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
(Date:10/25/2014)... 2014 The proposed consolidation of all ... in December, when the U.S. Judicial Panel on Multidistrict ... a Hearing Session Order issued by the Panel on ... heard on December 4, 2014, in Charleston, South Carolina. ... Re: Xarelto Products Liability Litigation, No. 2592) , “Our ...
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the ... in the field of establishing recovery community organizations. Bob ... when he retired, he set out to answer a couple ... , 1. Where are the people in recovery ... 2. Can the recovery community be organized to advocate for ...
(Date:10/25/2014)... October 25, 2014 QueenBeeTickets.com has a ... great selection at affordable prices. Bob Seger & The ... Center and Nationwide Arena are going on sale October ... Click Here to browse the selection of tickets ... QueenBeeTickets.com. , The famous singer is touring North America ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 Limbkeepers® announced ... episode of Innovations with Ed Begley Jr, airing 1st ... TBA. , In this episode, Innovations will focus on ... to protect fragile, thinning skin on arms, hands, and ... learn about these versatile products, which help reduce injuries, ...
(Date:10/25/2014)... Researchers who discovered antibiotics in farmed and wild ... The use of antibiotics in animals, including ... to the development of antibiotic-resistant bacteria that threaten ... study. Each year in the United States, ... kill about 23,000, according to the Infectious Diseases ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit News: JPML to Hear Oral Arguments on Proposed Xarelto Multidistrict Litigation at December Hearing, Bernstein Liebhard LLP Reports 3Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... Cosmecueticals, beauty aids that reportedly work like prescription drugs, ... study recently published in the Journal of Cosmetic Dermatology ... provide a visibly noticeable improvement in maturing skin. , ... the lack of skin surface regularity, formation of wrinkles, ...
... 28 Versus,Technology, Inc. ("Versus" or the "Company") ... October 31, 2007, compared to,revenues of $2,177,000 for ... year,ended October 31, 2007, were $5,566,000 compared to ... vary significantly depending on,the timing and delivery of ...
... MB Software,Corporation (OTC Bulletin Board: MBSB) announced ... Equity Partners to issue 490.196 shares of its,Series ... cancellation of,approximately $1,500,000 in debt. The debt was ... affiliates. The preferred stock will,automatically convert into an ...
... gadolinium-containing contrast injections in adults and pediatric patients (those ... to a recent study conducted by researchers at the ... these reactions do occur, most of them are mild, ... study. , Over the past few years, the ...
... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
... 28 Lincare Holdings,Inc. (Nasdaq: LNCR ) today ... and Exchange Commission (the "SEC") a resale shelf registration,statement ... pursuant to the terms,of a registration rights agreement Lincare ... sale of its $275 million principal amount of,convertible senior ...
Cached Medicine News:Health News:Versus Technology Announces Fourth Quarter Results 2Health News:Versus Technology Announces Fourth Quarter Results 3Health News:Versus Technology Announces Fourth Quarter Results 4Health News:Versus Technology Announces Fourth Quarter Results 5Health News:Versus Technology Announces Fourth Quarter Results 6Health News:Versus Technology Announces Fourth Quarter Results 7Health News:MB Software Corporation Reaches Agreement with Keystone Equity Partners 2Health News:Allergic reactions to gadolinium-based contrast agents are rare, study finds 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:Lincare Holdings Inc. Reports Intention to File Shelf Registration Statement 2
... including the Ceralas D and SmilePro 980 ... medical, dental, and veterinary environments.,With unsurpassed, optimal ... nm laser series allow controlled tissue ablation ... surgical procedures. Unlike other medical lasers, biolitecs ...
... Assay is a second generation nucleic acid ... in vitro qualitative detection and differentiation of ... uses a family of Gen-Probe's proven technologies ... and Dual Kinetic Assay (DKA). This is ...
... The InTray™ GC is a ... detection of both Neisseria gonorrhoeae and ... a long shelf life and is ... system. Simply inoculate, incubate and ...
... designed for patients with a spherical hyperopia between ... who would benefit from a spherical treatment of ... a myopic endpoint of between -1.00 D and ... improve near vision. CK is unique in that ...
Medicine Products: